Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer-Combination Strategies.

ABSTRACT:

Purpose of review

[¹⁷⁷Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate cancer. Despite its clinical success, there are still patients not showing sufficient response rates. This review compiles latest studies aiming at therapy improvement in [¹⁷⁷Lu]Lu-PSMA-617-naïve and -resistant patients by alternative or combination treatments.

Recent findings

A variety of agents to combine with [¹⁷⁷Lu]Lu-PSMA-617 are currently under investigation including alpha radiation-emitting pharmaceuticals, radiosensitizers, taxane chemotherapeutics, androgen receptor pathway inhibitors, immune checkpoint inhibitors, and external beam radiation. Actinium-225 (²²⁵

SUBMITTER: Arbuznikova D 

PROVIDER: S-EPMC10640479 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature